ESMO – Eur. Oncology shared an article by Stefan Symeonides on X:
“Early-phase trials presented at ESMOAsia24 report the potential for two new oral small-molecule ICIs in Solid Tumours showcasing favourable benefit-risk profiles and improved ease of use compared w/ antibodies.”
Two oral immune checkpoint inhibitors show preliminary efficacy and manageable safety in early trials.
Authors: Stefan Symeonides, et al.
